Promising Developments and Patent Milestone Bolster Buy Rating for Enveric BiosciencesOur $10 PT was derived by using a 13% rate to discount free cash flows from annual sales and payments from a prospective partner’s commercialization of EB-003, and dividing them by our projected number of shares for each year to account for the effects of share dilution, and then factoring in a 2% terminal growth rate and 25% clinical program probability of success.